GRAIL, Inc. (GRAL) Earnings Call Transcripts

GRAIL, Inc.'s Latest Earnings Call - June 9, 2026

In the Q2 2026 earnings call for GRAIL, Inc., management highlighted significant advancements in their multi-cancer early detection (MCED) technology, particularly following positive data from the NHS-Galleri trial. The company reported a revenue growth of 37% in Q1 and maintained guidance for 22% to 32% growth for the fiscal year, indicating strong market demand. Management emphasized the potential for FDA approval and the anticipated impact on future revenues, with an optimistic outlook on clinical utility supporting national coverage decisions.

Reported metrics

Guidance from management

Management maintained their revenue guidance for the fiscal year at 22% to 32%, indicating confidence in growth despite the strong performance in Q1. They will reassess guidance based on Q2 performance.

What management said

Yes. So the NHS will be doing a cost analysis. It's in I think sometime in '28 or '29 with mortality analysis and so on. So yes, we will be looking at that. And then I think other single-payer systems will see a lot of value in that. CMS, U.S. payers. We've got the REACH/Galleri study, where we're doing something similar to HS, where it's a 3 time point 5,000-person study in the Medicare population. They'll have data...

Yes. So they've just got access to the data. They've seen it, and they're excited by it. So I think no government makes a decision very quickly. We've always expected that to happen over an extended period of time. And there were multiple endpoints that they wanted to look at. One was the primary endpoint, but there were also others. So we'll be working with them to see what the next steps are. And once we have an id...

What analysts pressed on

Analysts expressed concerns regarding the timeline for FDA approval and the potential impact on revenue growth. There were also questions about the sustainability of profitability given the high costs associated with sales and marketing efforts.

Main topics on the call

• Positive NHS-Galleri Trial Results — Management reported a 'more than 20%' reduction in Stage IV cancer cases in the second year and 'more than 26%' in the third year of the NHS-Galleri trial, indicating significant clinical utility. They noted that 'standa...
• FDA Approval Progress — GRAIL is in an 'iterative review process' with the FDA for their PMA submission, with management expressing confidence in their submission. They expect to know soon if an Advisory Committee meeting will be required, whic...
• Sales Force Expansion — Management has expanded their sales force by 30 territories to drive growth, indicating a proactive approach to capitalize on the positive trial data. They expect this expansion to contribute to their revenue guidance of...
• Clinical Utility and Cost Savings — The company is preparing for a cost analysis by the NHS, which is expected to demonstrate significant cost savings associated with their testing. Management believes that the data will support national coverage decisions...

Read the full GRAIL, Inc. transcript (June 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 21 GRAIL, Inc. earnings call transcripts on record, spanning August 13, 2024 to August 5, 2026. Based on this history, GRAIL, Inc. reports quarterly. The most recent call on file is dated August 5, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

GRAL

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

21

First call

August 13, 2024

Most recent

August 5, 2026

Reporting cadence

quarterly